Mablink is incubated and supported by PULSALYS
Mablink receives a €380,000 equity investment from TTO PULSALYS to carry out the preclinical proof of concept of its ADC drug candidate MBK-102 in Non-Hodgkin’s Lymphoma.
Newsroom
New communication on Mablink by Puls@lys
After having earned the #FrenchTechSeed label in the middle of March, Puls@lys has made an exclusive communication on our Antibody-Drug linker technology as a breakthrough innovation as well as its …
Mablink has been awarded the R2B Onco 2019 Trophy
With more than 700 participants last April 4th/5th, the Auvergne-Rhône-Alpes Cancer Research Forum is one of the most federating events. During this event took place the Research2Business (R2B) Oncology Meeting …
Mablink earned the French Tech Seed Label
French Tech Seed labeled company. Our company has recently been granted with the French Tech Seed label which rewards DeepTech projects lead by young dynamic companies. Our highly potent technology …
Our article is now available in Chemical Science journal
A new peer-reviewed scientific publication introducing our ADC drug-linker platform is now available online. Abstract Antibody-drug conjugates (ADCs) convey highly potent anticancer drugs to antigen-expressing tumor cells, thereby sparing healthy …
New article on ChemRxiv
Our new publication is now available online. Abstract: We report the on-resin synthesis of monodisperse (i.e. discrete) polysarcosine compounds and their uses as an hydrophobicity masking entity for the construction of …